AU2016247674A1 - Compositions and methods of treatment of breast disorders and estrogen-related disorders - Google Patents
Compositions and methods of treatment of breast disorders and estrogen-related disorders Download PDFInfo
- Publication number
- AU2016247674A1 AU2016247674A1 AU2016247674A AU2016247674A AU2016247674A1 AU 2016247674 A1 AU2016247674 A1 AU 2016247674A1 AU 2016247674 A AU2016247674 A AU 2016247674A AU 2016247674 A AU2016247674 A AU 2016247674A AU 2016247674 A1 AU2016247674 A1 AU 2016247674A1
- Authority
- AU
- Australia
- Prior art keywords
- breast
- fatty acid
- composition
- vitamin
- omega
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562147536P | 2015-04-14 | 2015-04-14 | |
| US62/147,536 | 2015-04-14 | ||
| PCT/US2016/026170 WO2016168021A1 (en) | 2015-04-14 | 2016-04-06 | Compositions and methods of treatment of breast disorders and estrogen-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016247674A1 true AU2016247674A1 (en) | 2017-10-19 |
Family
ID=57127000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016247674A Abandoned AU2016247674A1 (en) | 2015-04-14 | 2016-04-06 | Compositions and methods of treatment of breast disorders and estrogen-related disorders |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180049999A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3283061A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018514511A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107708678A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016247674A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2981301A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016168021A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180169034A1 (en) * | 2015-06-14 | 2018-06-21 | Trs Ii, Llc | Transdermal delivery formulation |
| CA2992282A1 (en) * | 2015-07-14 | 2017-01-19 | Atossa Genetics Inc. | Transpapillary methods and compositions for treating breast disorders |
| CN110099680B (zh) | 2016-10-11 | 2021-02-05 | 杜克大学 | Er+乳腺癌的拉索昔芬治疗 |
| CN111212635A (zh) * | 2017-09-11 | 2020-05-29 | 阿托莎医疗公司 | 局部用组合物 |
| EP3681491A4 (en) | 2017-09-11 | 2021-06-30 | Atossa Therapeutics, Inc. | PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES |
| TW201919594A (zh) * | 2017-09-11 | 2019-06-01 | 美商艾陶莎基因有限公司 | 局部用組合物及治療方法 |
| CA3094072A1 (en) * | 2018-03-15 | 2019-09-19 | Atossa Therapeutics, Inc. | In situ methods of inducing of immune response |
| CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| WO2019232485A1 (en) * | 2018-05-31 | 2019-12-05 | Nvigen, Inc. | Accurate blood test to predict cancer incidence, recurrence, guide and monitor treatment intervention |
| US12390435B2 (en) | 2018-11-14 | 2025-08-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Electrophiles and electrophile pro-drugs as RAD51 inhibitors |
| IT201900003843A1 (it) * | 2019-03-15 | 2020-09-15 | Lo Li Pharma Srl | Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG) |
| EP3980006A2 (en) * | 2019-06-07 | 2022-04-13 | Diomics Corporation | Topical time release delivery using layered biopolymer |
| WO2021003433A1 (en) * | 2019-07-03 | 2021-01-07 | Atossa Therapeutics, Inc. | Sustained release compositions of endoxifen |
| BR112022001165A2 (pt) * | 2019-07-23 | 2022-05-17 | Scherer Technologies Llc R P | Formulações de cápsula de casca macia e métodos de preparação e uso das mesmas |
| US11915811B2 (en) * | 2019-09-03 | 2024-02-27 | Kaival Labs, Inc. | System and method for determining an appropriate dose of a product |
| KR20220154196A (ko) * | 2020-03-18 | 2022-11-21 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 연질겔 캡슐 |
| WO2021231904A1 (en) * | 2020-05-14 | 2021-11-18 | Diomics Corporation | Detection and indication of covid-19, other viruses and pathogens and vaccine associated efficacy |
| CN111420046B (zh) * | 2020-05-27 | 2021-01-12 | 四川省畜牧科学研究院 | 一种动物疫苗佐剂及其制备方法 |
| WO2022187511A1 (en) * | 2021-03-03 | 2022-09-09 | Veramorph Llc | Dissociating polymer matrix compositions of fulvestrant and methods of their making and use |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| KR102864596B1 (ko) * | 2022-04-25 | 2025-09-26 | 유엠에스엔지니어링 주식회사 | 오메가 3 심리스 연질캡슐 제조방법 |
| WO2025174794A1 (en) * | 2024-02-12 | 2025-08-21 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149851A (en) * | 1990-10-25 | 1992-09-22 | The United States Of America As Represented By The Secretary Of Commerce | Process for preparing triglycerides containing polyunsaturated fatty acid moieties |
| US5613958A (en) * | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
| DE19738643C2 (de) * | 1997-09-04 | 2001-10-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Scopolaminbase und Verfahren zu seiner Herstellung |
| WO2001001962A1 (en) * | 1999-07-05 | 2001-01-11 | Idea Ag. | A method for the improvement of transport across adaptable semi-permeable barriers |
| DE20013336U1 (de) * | 2000-08-02 | 2001-02-15 | Bieger, Wilfried P., Priv.-Doz. Dr.med.habil., 80335 München | Mund- und Zahnpflegegel |
| NZ552316A (en) * | 2006-12-22 | 2009-10-30 | Fonterra Co Operative Group | Dairy product and process |
| WO2008113177A1 (en) * | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| US20090068190A1 (en) * | 2007-08-29 | 2009-03-12 | Drugtech Corporation | Anti-proliferative combinations |
| WO2014093313A1 (en) * | 2012-12-10 | 2014-06-19 | Jingxuan Kang | Compositions and methods for integrated metabolic interventions |
| US8728546B1 (en) * | 2013-03-15 | 2014-05-20 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer, cardiovascular diseases and inflammation |
| MX370055B (es) * | 2013-04-22 | 2019-11-29 | Smartfish As | Uso de una composición que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cáncer. |
| CN103734512A (zh) * | 2013-12-20 | 2014-04-23 | 晓健科技(大连)有限公司 | 一种宠物猫补钙营养膏 |
| CA2992282A1 (en) * | 2015-07-14 | 2017-01-19 | Atossa Genetics Inc. | Transpapillary methods and compositions for treating breast disorders |
-
2016
- 2016-04-06 EP EP16780471.5A patent/EP3283061A4/en not_active Withdrawn
- 2016-04-06 AU AU2016247674A patent/AU2016247674A1/en not_active Abandoned
- 2016-04-06 CN CN201680034873.1A patent/CN107708678A/zh active Pending
- 2016-04-06 WO PCT/US2016/026170 patent/WO2016168021A1/en not_active Ceased
- 2016-04-06 US US15/561,249 patent/US20180049999A1/en not_active Abandoned
- 2016-04-06 JP JP2017550122A patent/JP2018514511A/ja active Pending
- 2016-04-06 CA CA2981301A patent/CA2981301A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2981301A1 (en) | 2016-10-20 |
| EP3283061A4 (en) | 2019-04-17 |
| EP3283061A1 (en) | 2018-02-21 |
| JP2018514511A (ja) | 2018-06-07 |
| WO2016168021A1 (en) | 2016-10-20 |
| CN107708678A (zh) | 2018-02-16 |
| US20180049999A1 (en) | 2018-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3283061A1 (en) | Compositions and methods of treatment of breast disorders and estrogen-related disorders | |
| RU2737496C2 (ru) | Способы лечения рака | |
| EP3630078B1 (en) | Chemoembolization agents | |
| CN115698013B (zh) | Menin抑制剂和cyp3a4抑制剂的组合及其使用方法 | |
| TW201927304A (zh) | 尼拉帕尼(niraparib)調配物 | |
| JP2006510655A (ja) | 高脂肪環境への活性物質の制御放出 | |
| CN111132670A (zh) | 具有增强的渗透的药物组合物 | |
| CN102413821A (zh) | 经皮吸收型制剂 | |
| JP7784400B2 (ja) | ホットフラッシュの新規処置法 | |
| CN102065900B (zh) | 经皮吸收促进剂和使用其的经皮给药制剂 | |
| TW200528144A (en) | Controlled release of topiramate in liquid dosage forms | |
| TW201919608A (zh) | 局部用組合物 | |
| TW201919594A (zh) | 局部用組合物及治療方法 | |
| TW200901989A (en) | Anti-tumor activity of CCI-779 in papillary renal cell cancer | |
| CN115843246B (zh) | 用于治疗血管瘤的方法和组合物 | |
| TW201325584A (zh) | 治療皮膚腫瘤的方法 | |
| KR102258514B1 (ko) | 신규한 다층형 좌약 제제 | |
| TW202532086A (zh) | 治療對卡介苗療法無反應之高風險非肌肉侵襲性膀胱癌之方法 | |
| WO2017148359A1 (zh) | 一种含有吡咯并六元杂环化合物或其可药用盐的药物组合物 | |
| HK40060074A (en) | Liposomal enhanced intra-peritoneal chemotherapy | |
| JP2009286759A (ja) | デンプンを素材とする徐放性支持体、および徐放性固形製剤への応用 | |
| CN113453667A (zh) | 脂质体增强腹腔内化学疗法 | |
| HK40027656B (en) | Chemoembolization agents | |
| WO2016135262A1 (en) | No donors for the treatment of impaired tissue perfusion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: ATOSSA GENETICS INC. Free format text: FORMER NAME(S): ATOSSA GENETICS, INC. |
|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |